BeOne Medicines' Sonrotoclax Receives FDA Priority Review for R/R MCL Treatment
- FDA Priority Review: BeOne Medicines' sonrotoclax has received FDA Priority Review, potentially becoming the first BCL2 inhibitor for relapsed/refractory (R/R) mantle cell lymphoma (MCL) in the U.S., addressing a significant unmet medical need in this aggressive cancer.
- Clinical Data Support: The NDA is backed by data from a global multicenter study involving 125 patients, demonstrating a clinically meaningful overall response rate in heavily pretreated individuals, highlighting sonrotoclax's therapeutic potential.
- Rapid Advancement: The swift transition from Breakthrough Therapy Designation to Priority Review underscores sonrotoclax's rapid, deep, and durable responses in clinical trials, positioning it as a potential best-in-class BCL2 inhibitor.
- International Collaboration: BeOne will participate in the FDA's Project Orbis to expedite global review processes and plans to submit data to other regulatory bodies, aiming for worldwide approval of sonrotoclax.
Trade with 70% Backtested Accuracy
Analyst Views on 06160
About the author
CICC Identifies Possible 'Blue Chip' Stocks for HSI Semi-Annual Adjustment Predictions (Table)
CICC Report on HSI Adjustments: CICC predicts potential blue chip stocks for inclusion in the HSI based on semi-annual adjustments and quantitative criteria, highlighting companies like ZIJIN GOLD INTL and YUM CHINA.
Short Selling and Inflows: The report details short selling ratios and inflows for various stocks, indicating market activity and investor sentiment towards companies such as BEONE MEDICINES and XPENG-W.
Potential Replacements for HANG SENG BANK: Following the delisting of HANG SENG BANK, companies like STANCHART and SWIREPROPERTIES are identified as potential candidates to fill the vacancy.
Market Performance Overview: The report includes a snapshot of stock performance, with some companies experiencing gains while others face declines, reflecting the mixed market conditions.
CICC Forecasts Inclusion of ZIJIN GOLD INTL, BEONE MEDICINES, PICC P&C, and AKESO in HSI; STANCHART Likely to Take HANG SENG BANK's Place
Annual Review Announcement: The Hang Seng Indexes Company will announce the results of its annual review of major Hong Kong stock indices on February 13, which will impact the eligible stocks for Southbound Stock Connect.
Potential New Additions: CICC forecasts that ZIJIN GOLD INTL, YUM CHINA, and BEONE MEDICINES are likely to meet the inclusion criteria for the Hang Seng Index, while several other companies may fill the gap left by HANG SENG BANK's removal.
Market Capitalization Considerations: Companies like STANCHART, SWIREPROPERTIES, and SINO LAND are also potential candidates for inclusion based on market capitalization and industry coverage, though their inclusion remains uncertain.
Southbound Stock Connect Adjustments: CICC anticipates that 44 stocks, including JD INDUSTRIALS and CHUANGXIN IND, will become eligible for inclusion in Southbound Stock Connect, while 25 stocks may be removed from the list.
BEONE MEDICINES' 'Baiyue Da' Achieves First Sales Transaction in Beijing
Product Launch: CHINA NATIONAL MEDICINE has been appointed as the preferred distributor for BEONE MEDICINES' new product, Baiyue Da, in Beijing.
Successful Delivery: The first order delivery of Baiyue Da was completed efficiently, with the medication arriving at Sinopharm Logistics and reaching the designated pharmacy within three hours.
Collaboration: The successful delivery was made possible through the cooperation of CHINA NATIONAL MEDICINE's procurement center, Beijing direct sales center, and Sinopharm Logistics.
Market Activity: BEONE MEDICINES is experiencing short selling activity, with a reported short selling amount of $134.34 million and a ratio of 12.328%.
HSI Rises 123 Points at Opening; Pharmaceutical Stocks Surge; HAIDILAO Jumps Over 5%
US Stock Market Performance: US stocks fell 398 points (0.8%) following JPMorgan's earnings report, while chip stocks saw increased interest.
Hong Kong Market Opening: The Hong Kong bourse opened higher, with the HSI up 123 points (0.5%) and notable gains in tech stocks like BABA-W and TENCENT.
Inflation Rate in China: China's inflation rate for December was reported at 0.8%, slightly above the previous 0.7% but below the forecast of 0.9%.
Pharmaceutical Sector Activity: Several pharmaceutical stocks, including HANSOH PHARMA and BEONE MEDICINES, opened higher, while PHARMARON anticipated a decrease in full-year profit but still saw a slight increase in stock price.
HKEX Introduces Six New Classes of Stock Options
New Stock Options Launch: HKEX is set to launch six new stock option classes on January 19, 2026, enhancing choices for investors in the single stock options market.
Included Stocks: The new options will include stocks such as ZIJIN GOLD INTL, WUXI APPTEC, BEONE MEDICINES, LAOPU GOLD, HORIZONROBOT-W, and AKESO, each with varying short selling data and ratios.
BeOne Reports ZIIHERA Trial Results, Significant Survival Improvement Observed
- Survival Breakthrough: The HERIZON-GEA-01 trial demonstrated that the combination of ZIIHERA and TEVIMBRA with chemotherapy achieved a median overall survival of 26.4 months, resulting in a 28% reduction in the risk of death compared to the control group, marking a significant advancement in the treatment of HER2+ gastroesophageal adenocarcinoma.
- Clinical Efficacy: The trial met its dual primary endpoints, with the ZIIHERA plus TEVIMBRA arm showing statistically significant improvements in both progression-free survival (PFS) and overall survival (OS) compared to the control arm, highlighting its potential in treatment.
- Expanded Patient Benefit: BeOne holds commercial rights for ZIIHERA in the Asia-Pacific region, and with these results, the company anticipates expanding access to treatment for more patients, addressing the urgent need for new therapies in the region.
- Favorable Safety Profile: The safety profile of ZIIHERA in combination with TEVIMBRA and chemotherapy was consistent with known effects of HER2-targeted therapies, with no new safety signals identified, supporting its feasibility in first-line treatment settings.
CICC Identifies Possible 'Blue Chip' Stocks for HSI Semi-Annual Adjustment Predictions (Table)
CICC Report on HSI Adjustments: CICC predicts potential blue chip stocks for inclusion in the HSI based on semi-annual adjustments and quantitative criteria, highlighting companies like ZIJIN GOLD INTL and YUM CHINA.
Short Selling and Inflows: The report details short selling ratios and inflows for various stocks, indicating market activity and investor sentiment towards companies such as BEONE MEDICINES and XPENG-W.
Potential Replacements for HANG SENG BANK: Following the delisting of HANG SENG BANK, companies like STANCHART and SWIREPROPERTIES are identified as potential candidates to fill the vacancy.
Market Performance Overview: The report includes a snapshot of stock performance, with some companies experiencing gains while others face declines, reflecting the mixed market conditions.
CICC Forecasts Inclusion of ZIJIN GOLD INTL, BEONE MEDICINES, PICC P&C, and AKESO in HSI; STANCHART Likely to Take HANG SENG BANK's Place
Annual Review Announcement: The Hang Seng Indexes Company will announce the results of its annual review of major Hong Kong stock indices on February 13, which will impact the eligible stocks for Southbound Stock Connect.
Potential New Additions: CICC forecasts that ZIJIN GOLD INTL, YUM CHINA, and BEONE MEDICINES are likely to meet the inclusion criteria for the Hang Seng Index, while several other companies may fill the gap left by HANG SENG BANK's removal.
Market Capitalization Considerations: Companies like STANCHART, SWIREPROPERTIES, and SINO LAND are also potential candidates for inclusion based on market capitalization and industry coverage, though their inclusion remains uncertain.
Southbound Stock Connect Adjustments: CICC anticipates that 44 stocks, including JD INDUSTRIALS and CHUANGXIN IND, will become eligible for inclusion in Southbound Stock Connect, while 25 stocks may be removed from the list.
BEONE MEDICINES' 'Baiyue Da' Achieves First Sales Transaction in Beijing
Product Launch: CHINA NATIONAL MEDICINE has been appointed as the preferred distributor for BEONE MEDICINES' new product, Baiyue Da, in Beijing.
Successful Delivery: The first order delivery of Baiyue Da was completed efficiently, with the medication arriving at Sinopharm Logistics and reaching the designated pharmacy within three hours.
Collaboration: The successful delivery was made possible through the cooperation of CHINA NATIONAL MEDICINE's procurement center, Beijing direct sales center, and Sinopharm Logistics.
Market Activity: BEONE MEDICINES is experiencing short selling activity, with a reported short selling amount of $134.34 million and a ratio of 12.328%.
HSI Rises 123 Points at Opening; Pharmaceutical Stocks Surge; HAIDILAO Jumps Over 5%
US Stock Market Performance: US stocks fell 398 points (0.8%) following JPMorgan's earnings report, while chip stocks saw increased interest.
Hong Kong Market Opening: The Hong Kong bourse opened higher, with the HSI up 123 points (0.5%) and notable gains in tech stocks like BABA-W and TENCENT.
Inflation Rate in China: China's inflation rate for December was reported at 0.8%, slightly above the previous 0.7% but below the forecast of 0.9%.
Pharmaceutical Sector Activity: Several pharmaceutical stocks, including HANSOH PHARMA and BEONE MEDICINES, opened higher, while PHARMARON anticipated a decrease in full-year profit but still saw a slight increase in stock price.
HKEX Introduces Six New Classes of Stock Options
New Stock Options Launch: HKEX is set to launch six new stock option classes on January 19, 2026, enhancing choices for investors in the single stock options market.
Included Stocks: The new options will include stocks such as ZIJIN GOLD INTL, WUXI APPTEC, BEONE MEDICINES, LAOPU GOLD, HORIZONROBOT-W, and AKESO, each with varying short selling data and ratios.
BeOne Reports ZIIHERA Trial Results, Significant Survival Improvement Observed
- Survival Breakthrough: The HERIZON-GEA-01 trial demonstrated that the combination of ZIIHERA and TEVIMBRA with chemotherapy achieved a median overall survival of 26.4 months, resulting in a 28% reduction in the risk of death compared to the control group, marking a significant advancement in the treatment of HER2+ gastroesophageal adenocarcinoma.
- Clinical Efficacy: The trial met its dual primary endpoints, with the ZIIHERA plus TEVIMBRA arm showing statistically significant improvements in both progression-free survival (PFS) and overall survival (OS) compared to the control arm, highlighting its potential in treatment.
- Expanded Patient Benefit: BeOne holds commercial rights for ZIIHERA in the Asia-Pacific region, and with these results, the company anticipates expanding access to treatment for more patients, addressing the urgent need for new therapies in the region.
- Favorable Safety Profile: The safety profile of ZIIHERA in combination with TEVIMBRA and chemotherapy was consistent with known effects of HER2-targeted therapies, with no new safety signals identified, supporting its feasibility in first-line treatment settings.
